Royal Bank of Canada
BIO icon

Royal Bank of Canada’s Bio-Rad Laboratories Class A BIO Stock Holding History

Royal Bank of Canada’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-303,200
Closed -$60.4M – 6559
2017
Q1 		$60.4M Buy
+303,200
New +$58.4M 0.03% 440

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's BIO Position: Q1 2026 in Review

Royal Bank of Canada increased its Bio-Rad Laboratories Class A (BIO) stake by 17% in Q1 2026, buying an estimated $716K and bringing the position to 17,198 shares worth $4.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Royal Bank of Canada first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $49.4M in Q3 2025. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Royal Bank of Canada held 17,198 shares of Bio-Rad Laboratories Class A worth $4.79M as of Q1 2026.
  • Royal Bank of Canada bought 2,487 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $716K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2445 holding.
  • Royal Bank of Canada first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Bio-Rad Laboratories Class A position peaked at $49.4M in Q3 2025.
  • 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.